Cargando…

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma

Antibodies against programmed cell death-1 (PD-1) have considerably changed the treatment for melanoma. However, many patients do not display therapeutic response or eventually relapse. Moreover, patients treated with anti-PD-1 develop immune-related adverse events that can be cured with anti-tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bertrand, Florie, Montfort, Anne, Marcheteau, Elie, Imbert, Caroline, Gilhodes, Julia, Filleron, Thomas, Rochaix, Philippe, Andrieu-Abadie, Nathalie, Levade, Thierry, Meyer, Nicolas, Colacios, Céline, Ségui, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741628/ https://www.ncbi.nlm.nih.gov/pubmed/29273790 http://dx.doi.org/10.1038/s41467-017-02358-7

Ejemplares similares

Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
por: Imbert, Caroline, et al.
Publicado: (2020)

The TNF Paradox in Cancer Progression and Immunotherapy
por: Montfort, Anne, et al.
Publicado: (2019)

Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy
por: Montfort, Anne, et al.
Publicado: (2019)

Anti-TNF, a magic bullet in cancer immunotherapy?
por: Montfort, Anne, et al.
Publicado: (2019)

Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma
por: Bilal, Fatima, et al.
Publicado: (2019)

TNF-R1, an immune checkpoint in melanoma?
por: Bertrand, Florie, et al.
Publicado: (2015)

New Insights into the Role of Sphingolipid Metabolism in Melanoma
por: Carrié, Lorry, et al.
Publicado: (2020)

Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanoma
por: Mrad, Marguerite, et al.
Publicado: (2016)

The Tricyclodecan-9-yl-xanthogenate D609 Triggers Ceramide Increase and Enhances FasL-Induced Caspase-Dependent and -Independent Cell Death in T Lymphocytes
por: Milhas, Delphine, et al.
Publicado: (2012)

Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast Cancer
por: Marcheteau, Elie, et al.
Publicado: (2021)

Sphingolipids modulate the epithelial–mesenchymal transition in cancer
por: Levade, T, et al.
Publicado: (2015)

Caspase-10-Dependent Cell Death in Fas/CD95 Signalling Is Not Abrogated by Caspase Inhibitor zVAD-fmk
por: Lafont, Elodie, et al.
Publicado: (2010)

Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives
por: Pellerin, Laurence, et al.
Publicado: (2020)

Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses
por: Dubot, Patricia, et al.
Publicado: (2020)

Potential Role of Sphingolipidoses-Associated Lysosphingolipids in Cancer
por: Dubot, Patricia, et al.
Publicado: (2022)

Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
por: Chen, Xingyu, et al.
Publicado: (2022)

Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
por: de Streel, Grégoire, et al.
Publicado: (2020)

Lin(−)CCR2(+) hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade
por: Flores, Catherine T., et al.
Publicado: (2018)

Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer
por: Miao, Yu Rebecca, et al.
Publicado: (2021)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
por: Wang, Man, et al.
Publicado: (2023)

Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity
por: Alvarez, Maite, et al.
Publicado: (2019)

PD-1 and TIGIT blockade differentially affect tumour cell survival under hypoxia and glucose deprived conditions in oesophageal adenocarcinoma; implications for overcoming resistance to PD-1 blockade in hypoxic tumours
por: Davern, Maria, et al.
Publicado: (2022)

TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model
por: Siewe, Nourridine, et al.
Publicado: (2021)

Targeting Alpha‐Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD‐1 Blockade Immunotherapy in Renal Cell Carcinoma
por: Li, Le, et al.
Publicado: (2023)

Combinations using checkpoint blockade to overcome resistance
por: Morganti, Stefania, et al.
Publicado: (2020)

IL-6 Deficiency Attenuates Murine Diet-Induced Non-Alcoholic Steatohepatitis
por: Mas, Emmanuel, et al.
Publicado: (2009)

PD-1 Blockade Overcomes Adaptive Immune Resistance in Treatment with Anchored-GM-CSF Bladder Cancer Cells Vaccine
por: Zhang, Xinji, et al.
Publicado: (2018)

Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer
por: Wang, Yumeng, et al.
Publicado: (2022)

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
por: Minnar, Christine M, et al.
Publicado: (2022)

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1(hi)CD39(+) CD4 T cells
por: Balança, Camille-Charlotte, et al.
Publicado: (2021)

Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance
por: Liang, Yong, et al.
Publicado: (2018)

Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance
por: Zheng, Wenxin, et al.
Publicado: (2016)

Comparison of Variable Selection Methods for Time-to-Event Data in High-Dimensional Settings
por: Gilhodes, Julia, et al.
Publicado: (2020)

In vivo Effects in Melanoma of ROCK Inhibition-Induced FasL Overexpression
por: Teiti, Iotefa, et al.
Publicado: (2015)

PD-1 Blockade on Tumor Microenvironment-Resident ILC2s Promotes TNF-α Production and Restricts Progression of Metastatic Melanoma
por: Howard, Emily, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors
por: Huang, Tinglei, et al.
Publicado: (2021)

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma
por: Ribas, Antoni, et al.
Publicado: (2021)

Blockade of innate inflammatory cytokines TNFα, IL-1β, or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression
por: Walsh, Michael J, et al.
Publicado: (2023)

The Changing Face of Spondyloarthropathies Under TNF α Blockade
por: Elkayam, Ori, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_spg2c7ha5p5r5l6ic7q0m0545t